These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8687496)

  • 1. Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites.
    Pickard M; Kinsella A
    Biochem Pharmacol; 1996 Aug; 52(3):425-31. PubMed ID: 8687496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
    Kinsella AR; Smith D; Pickard M
    Br J Cancer; 1997; 75(7):935-45. PubMed ID: 9083327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis.
    Pickard M; Dive C; Kinsella AR
    Br J Cancer; 1995 Dec; 72(6):1389-96. PubMed ID: 8519649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based model for tumor drug resistance.
    Kuczek T; Chan TC
    Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts.
    Kinsella AR; Haran MS
    Cancer Res; 1991 Apr; 51(7):1855-9. PubMed ID: 2004369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The enhancement of the frequency of resistance to N-phosphonoacetyl-L-aspartate and methotrexate by 1-beta-D-arabinofuranosylcytosine: the effect of dipyridamole.
    Goz B; Jeffs L
    J Pharmacol Exp Ther; 1994 Aug; 270(2):480-4. PubMed ID: 8071840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles.
    Poupon MF; Smith KA; Chernova OB; Gilbert C; Stark GR
    Mol Biol Cell; 1996 Mar; 7(3):345-54. PubMed ID: 8868464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
    Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
    Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of N-(phosphonacetyl)-L-aspartate resistant Chinese hamster mutants in the presence of the uridine uptake inhibitor dipyridamole.
    Tessera L; Mucciolo E; Bertoni L; Giulotto E
    Anticancer Res; 1995; 15(1):189-92. PubMed ID: 7733632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
    Cole PD; Smith AK; Kamen BA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TPA enhancement of the recovery of methotrexate and N-phosphonacetyl L-aspartate resistant mouse 3T6 cell clones is associated with transient alterations of cell cycle progression.
    Szallasi A; Fox M; Kinsella AR
    Int J Cancer; 1988 Jul; 42(1):84-6. PubMed ID: 3391707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
    Zhen YS; Taniki T; Weber G
    Oncol Res; 1992; 4(2):73-8. PubMed ID: 1596584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
    Huang A; Fan H; Taylor WR; Wright JA
    Cancer Res; 1997 Nov; 57(21):4876-81. PubMed ID: 9354452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
    Cillo C; Ling V; Hill RP
    Int J Cancer; 1989 Jan; 43(1):107-11. PubMed ID: 2910823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hamster cells with increased rates of DNA amplification, a new phenotype.
    Giulotto E; Knights C; Stark GR
    Cell; 1987 Mar; 48(5):837-45. PubMed ID: 3815526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
    Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
    Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.